The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals announced topline results from LUCIA, its second pivotal Phase 3 clinical trial for DURAVYU for the treatment of wet age-related macular degeneration (AMD).
The company did not disclose specific details or data from the trial in its tweet. This update marks a significant milestone as DURAVYU progresses through the development pipeline focused on therapies for wet AMD.
View post on X Loading...
Earlier, Eyepoint Pharmaceuticals shared new DURAVYU Phase 3 LUGANO data and real world findings at RetinaSociety2026, according to company disclosures. The LUGANO trial previously provided additional insight into DURAVYU’s development for wet AMD. The latest LUCIA topline results represent a continuation of the company’s efforts in advancing this therapy.